Publication Name	World Journal of Clinical Cases
Manuscript ID	72173
Country	China

Received	2021-10-11 12:05
Peer-Review Started	2021-10-11 12:07
To Make the First Decision
Return for Revision	2021-11-07 04:17
Revised	2021-11-18 14:49
Second Decision	2022-01-04 03:26
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2022-01-05 02:48
Articles in Press	2022-01-05 02:48
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2022-01-07 09:04
Publish the Manuscript Online	2022-02-11 05:55

ISSN	2307-8960 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright	©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Medicine, General & Internal
Manuscript Type	Case Report
Article Title	Vedolizumab-associated diffuse interstitial lung disease in patients with ulcerative colitis: A case report
Manuscript Source	Unsolicited Manuscript
All Author List	Jie Zhang, Mei-Hong Liu, Xue Gao, Chang Dong and Yan-Xia Li
ORCID	Author(s) ORCID Number Jie Zhang http://orcid.org/0000-0002-4244-5660 Mei-Hong Liu http://orcid.org/0000-0002-0061-0373 Xue Gao http://orcid.org/0000-0002-3894-7561 Chang Dong http://orcid.org/0000-0001-5203-0891 Yan-Xia Li http://orcid.org/0000-0002-1586-5352
Funding Agency and Grant Number	Funding Agency Grant Number Dalian Municipal Science and Technology Innovation Foundation 2020JJ27SN072
Corresponding Author	Chang Dong, MD, Associate Chief Physician, Associate Professor, Department of Pulmonary and Critical Care Medicine, First Affiliated Hospital of Dalian Medical University, No. 222 Zhongshan Road, Xigang District, Dalian 116011, Liaoning, China. dongchang8793@163.com
Key Words	Vedolizumab; Adverse effects; Ulcerative colitis; Inflammatory bowel disease; Interstitial lung disease; Case report
Core Tip	Vedolizumab is the treatment of choice for patients with moderate-to-severe ulcerative colitis who are refractory to tumor necrosis factor antagonists. However, some rare but potentially lethal drug-associated adverse effects warrant pharmacovigilance. We present a case of new-onset diffuse parenchymal lung disease development under treatment with vedolizumab in a patient with ulcerative colitis. After two doses of vedolizumab, he developed persistent fever, progressively worsening dyspnea and eventually died of respiratory failure. The patient was eventually diagnosed with vedolizumab-related interstitial lung disease, in spite of the few case reports found after reviewing the literature. We aim to raise gastroenterologists’ and pulmonologists’ vigilance to this uncommon adverse event.
Publish Date	2022-02-11 05:55
Citation	Zhang J, Liu MH, Gao X, Dong C, Li YX. Vedolizumab-associated diffuse interstitial lung disease in patients with ulcerative colitis: A case report. World J Clin Cases 2022; 10(5): 1716-1722
URL	https://www.wjgnet.com/2307-8960/full/v10/i5/1716.htm
DOI	https://dx.doi.org/10.12998/wjcc.v10.i5.1716

Full Article (PDF)	WJCC-10-1716.pdf
Full Article (Word)	WJCC-10-1716.docx
Manuscript File	72173_Auto_Edited.docx
Answering Reviewers	72173-Answering reviewers.pdf
Audio Core Tip	72173-Audio core tip.m4a
Conflict-of-Interest Disclosure Form	72173-Conflict-of-interest statement.pdf
Copyright License Agreement	72173-Copyright license agreement.pdf
Approved Grant Application Form(s) or Funding Agency Copy of any Approval Document(s)	72173-Grant application form(s).pdf
Signed Consent for Treatment Form(s) or Document(s)	72173-Informed consent statement.pdf
Non-Native Speakers of English Editing Certificate	72173-Language certificate.pdf
Peer-review Report	72173-Peer-review(s).pdf
Scientific Misconduct Check	72173-Bing-Ma YJ-2.png
Scientific Editor Work List	72173-Scientific editor work list .pdf